Answers are grounded in this paper and cite their sources.
India's decision to waive local clinical trials for drugs approved in countries like the U.S., U.K., Japan, and the European Union represents a pivotal regulatory shift. While the move aims to expedite access to essential medications and enhance market availability, it raises significant concerns about patient safety, research and development (R&D), and broader healthcare implications.1
No takes yet. Share an insight, caveat, or question.
Rajmohan Seetharaman (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: